Abstract
To evaluate the safety and VEGFR-3 imaging effects of [68Ga]Ga-NOTA-(TMVP1)2 in ovarian cancer patients. 13 patients with ovarian cancer were recruited and underwent radionuclide imaging with [68Ga]Ga-NOTA-(TMVP1)2. The safety of [68Ga]Ga-NOTA-(TMVP1)2 was assessed in vivo (including vital signs, biochemical indices, ECG, allergic reactions, etc.) and its imaging effect on VEGFR-3 was explored. A total of 1 patient with primary ovarian cancer and 12 patients with recurrent ovarian cancer, with an age range of 41-54 years, were included in the study. 13 ovarian cancer patients had a total of 49 18F-FDG-positive lesions, 63.3% of which were positive for [68Ga]Ga-NOTA-(TMVP1)2. The higher expression of VEGFR-3 in [68Ga]Ga-NOTA-(TMVP1)2-positive ovarian cancer lesions was found by immunohistochemical staining, which was positively correlated. Meanwhile, [68Ga]Ga-NOTA-(TMVP1)2 is a safe radiotracer as no significant side effects have been found in the human. In conclusion, [68Ga]Ga-NOTA-(TMVP1)2 enables precise molecular imaging of VEGFR-3 in ovarian cancer patients with a favourable safety profile, providing a new tool for the in vivo assessment of VEGFR-3 in ovarian cancer.